46 results about "Riluzole" patented technology

The invention discloses a stable medicinal combination which contains active ingredient riluzole and pharmaceutical auxiliary material. The medicine combination is mainly used for the clinical treatment of amyotrophic lateral sclerosis.

The present invention relates to an agent for protecting a motor nerve of a patient with amyotrophic lateral sclerosis, which comprises a combination of (a) (2R)-2-propyloctanoic acid or a salt thereof and (b) a therapeutic agent for amyotrophic lateral sclerosis such as riluzole. An agent comprising a combination of (a) (2R)-2-propyloctanoic acid which is orally administered once a day in an amount per dose of about 1200 mg and (b) riluzole which is orally administered twice a day in an amount per dose of about 50 mg is useful for protecting a motor nerve in a patient(s) with amyotrophic lateral sclerosis. The agent can also suppress the respiratory disability associated with the progression of the disease condition and improve the survival rate of the patient(s).

Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.

The subject invention provides a method of providing neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection comprising periodically administering to the subject an amount of glatiramer acetate and an amount of 2-amino-6-trifluoromethoxybenzathiazole, wherein the amounts when taken together are effective to provide neuroprotection to the central or peripheral nervous system of the subject. The subject invention also provides a package comprising glatiramer acetate, 2-amino-6-trifluorormethoxybenzothiazole and instructions for use together to provide neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection. Additionally, the subject invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of 2-amino-6-trifluorormethoxybenzothiazole, wherein the amounts when taken together are effective to provide neuroprotection to the central or peripheral nervous system of the subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of 2-amino-6-trifluorormethoxybenzothiazole, which combination is useful to provide neuroprotection to the central or peripheral nervous system of the subject. In addition, the combination therapy may be used to treat a subject afflicted with multiple sclerosis or one afflicted with amyotrophic lateral sclerosis.

The invention pertains to the field of traditional Chinese medicine, in particular to a medicine preparation for treating amyotrophic lateral sclerosis and a preparation method thereof. The medicine preparation adopts the treatment principles of benefiting qi, nourishing yin and reinforcing yang, the traditional Chinese medicine compound preparation is prepared by taking pharmaceutical raw materials of membranous milkvetch root, dried rehmannia root, epimedium herb, medicinal Indianmulberry root and common macrocarpium fruit; the clinical studies show that the medicine preparation can significantly reduce the clinical integral of the traditional Chinese medicine symptoms of flaccidity diseases and improve the clinical symptoms of the patients with the flaccidity diseases / ALS; compared with the prior art, the treatment effects are significantly improved, furthermore, the medicine preparation is safe, reliable and has no nausea, vomit, decreased appetite, abdominal distension or other evident common side effects of riluzole.

Methods for the treatment of multiple sclerosis are disclosed comprising administering 6-(triflouromethoxy)-2-benzothiazolamine or a salt thereof.

The invention relates to a riluzole orally disintegrating tablet and a preparation method thereof, and belongs to the field of preparations. The tablet is prepared from riluzole, sodium bicarbonate, afilling agent, a disintegrating agent, a lubricating agent and a flavoring agent. The preparation method comprises the following steps of (1) weighing riluzole, sodium bicarbonate and filler according to prescription amounts, and uniformly mixing the riluzole, the sodium bicarbonate and the filler with 50% of the disintegrating agent according to prescription amounts for later use; 2) adding themixture obtained in the step 1) into an ethanol water solution, granulating, drying, and sieving to obtain dry granules for later use; and 3) adding 50% of a prescription amount of the disintegratingagent and a prescription amount of the flavoring agent into the dry particles obtained in the step 2, uniformly mixing, adding a prescription amount of the lubricant, uniformly mixing, and pressing toobtain the riluzole orally disintegrating tablet. The orally disintegrating tablet prepared by the invention has the advantages of short disintegration time limit, high dissolution rate and no gravelfeeling, meets the quality standard requirement of the orally disintegrating tablet, and is suitable for industrial scale-up production.

This invention relates to pharmaceutical compositions of riluzole in combination with levodopa and methods of treating Parkinson's disease and alleviating levodopa-induced dyskinesia and tardive dyskinesia therewith. Pharmaceutical compositions of riluzole in combination with an antipsychotic drug are also provided for use in the treatment of behavioral and psychiatric disorders treatable with an antipsychotic drug.

A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and / or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in neuroprotection of the latter, or a pharmaceutically acceptable salt of the latter.

The invention provides riluzole tablets and a preparation method thereof. The riluzole tablets comprise riluzole, polyethylene glycol, an N-vinyl pyrrolidone / vinyl acetate linear copolymer, a filling agent, a disintegrating agent and a lubricating agent. According to the invention, riluzole and polyethylene glycol are melted firstly, then the melted riluzole and polyethylene glycol are added into an ethanol solution of the N-vinyl pyrrolidone / vinyl acetate linear copolymer, and finally the corresponding filling agent, the disintegrating agent and the lubricating agent are added for tabletting, so that the riluzole tablets are obtained. The dissolution effect of the prepared riluzole tablets is improved obviously and can reach 80% or above with 10 min, the long-term storage stability is good, the preparation process is simple, complex equipment is not required and industrial mass production is facilitated.

A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and / or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in neuroprotection of the latter, or a pharmaceutically acceptable salt of the latter.

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions and kits including the immunotherapeutic agents and glutamate modulating agents are also disclosed.

Disclosed is a method of treating melanoma in a mammal comprising administering (a) a therapeutically effective amount of an inhibitor of metabotropic glutamate receptor 1 (GRM1); and (b) a therapeutically effective amount of an inhibitor of at least one downstream signaling target of GRM1. Also disclosed are compositions and kits for treating melanoma comprising (a) a therapeutically effective amount of an inhibitor of GRM1; and (b) a therapeutically effective amount of an inhibitor of at least one downstream signaling target of GRM1.

The invention belongs to the technical field of pharmaceutical preparations and discloses a Riluzole sustained-release oral-administration suspension. The Riluzole sustained-release oral-administration suspension is used for simultaneously solving problems in smooth release of drugs and compliance of drug administration of people suffering from dysphagia such as the elderly and children. The disclosed sustained-release suspension is prepared through dispersing Riluzole sustained-release microspheres in a solution containing a diluent, a flavoring agent, a suspending agent, a preservative and apH buffering agent, wherein the Riluzole sustained-release microspheres are prepared through dissolving Riluzole in an aqueous dispersion of ethyl cellulose and carrying out spray drying. Compared with common tablets, capsules and oral-administration suspensions on the market at present, the Riluzole sustained-release oral-administration suspension disclosed by the invention has the advantages that drug release is smooth, the number of times of drug administration is reduced, the quality is stable, the mouth feel is good, the compliance of drug administration is high, and the Riluzole sustained-release oral-administration suspension is applicable to the people suffering from the dysphagia such as the elderly and the children.

Physically and chemically stable aqueous oral suspensions of riluzole and manufacturing methods thereof. The suspensions contain riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is present in amounts from about 0.1% to about 20% w / v and has an average particle size lower than 200 μm. The suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.

Disclosed are methods of treating Alzheimer's Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzoleprodrugs are also disclosed.

Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan / quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB) / tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

The invention provides application of a non-hormone compound riluzole in treatment of oligospermia, provides beneficial help for solving the problem of male infertility, and has potential application prospects in the field of medicines.

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

The invention relates to a riluzole orally disintegrating tablet and a preparation method thereof, belonging to the field of preparations. The tablet is prepared from riluzole, sodium bicarbonate, filler, disintegrant, lubricant and flavoring agent. The preparation method is as follows: 1) Weigh the prescribed amount of riluzole, sodium bicarbonate, filler and 50% of the prescribed amount of disintegrant, mix evenly, and prepare the mixture for later use; 2) add the mixture in step 1 to granulate with ethanol aqueous solution, and dry After sieving, the dry granules are ready for use; 3) Add 50% of the disintegrating agent of the prescribed amount and the flavoring agent of the prescribed amount to the dry granules of step 2, mix evenly, then add the lubricant of the prescribed amount, mix evenly, and compress to obtain Riluzole orally disintegrating tablet. The orally disintegrating tablet prepared by the invention has short disintegration time limit, high dissolution rate and no gritty feeling, meets the quality standard requirements of the orally disintegrating tablet, and is suitable for industrial scale-up production.

An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example., epilepsy and seizures, by administering the oral film disclosed herein.

Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt or prodrug thereof, in the form of an oral solid molded fast-dispersing dosage form. Pharmaceutical compositions and kits are also disclosed.

The present invention provides a method for providing neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection, which comprises periodically administering to the subject a certain amount of glatiramer acetate and a certain amount of 2-amino-6 - Trifluoromethoxybenzothiazole, wherein said amount is effective to provide neuroprotection to said subject's central or peripheral nervous system when taken together. The present invention also provides a package comprising glatiramer acetate, 2-amino-6-trifluoromethoxybenzothiazole, and a composition for use together to provide neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection. Neuroprotective Instructions for Use. Furthermore, the present invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of 2-amino-6-trifluoromethoxybenzothiazole, wherein said amounts are effective to provide for Neuroprotection of the subject's central or peripheral nervous system. The present invention also provides a pharmaceutical combination comprising a certain amount of glatiramer acetate and a certain amount of 2-amino-6-trifluoromethoxybenzothiazole in separate dosage forms, the combination is effective for providing Neuroprotection of the central or peripheral nervous system. Additionally, the combination therapy may be used to treat a subject afflicted with multiple sclerosis or a subject afflicted with amyotrophic lateral sclerosis.